Advancing scientific understanding of the drive to socially engage: from broad constructs to transdiagnostic 'building blocks'
- PMID: 40858780
- DOI: 10.1038/s41380-025-03185-9
Advancing scientific understanding of the drive to socially engage: from broad constructs to transdiagnostic 'building blocks'
Abstract
Reduced drive to socially engage is observed across neurodevelopmental and neuropsychiatric conditions. However, previous research has relied on disorder-specific conceptualizations and measurement approaches that might obscure important differences in how social drive manifests and its underlying neurobiological mechanisms, both within and across different diagnostic categories. In this commentary, we argue that a model of reward processing that deconstructs social drive into 'orienting', 'wanting', 'pursuing', 'liking' and 'learning' processes can advance mechanistic and phenomenological understanding. Implementing this framework necessitates a multimethod measurement approach, combining rigorously validated behavioral measures and neurobiological sampling while leveraging specific developmental principles within a longitudinal research framework. Through these concerted efforts, the field will make significant strides towards developing a biologically grounded account of clinical phenomena characterized by different profiles of atypical drive to engage with others, which is a first and critical step toward the development of accurate prediction models and specific treatments.
© 2025. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: This project was supported by grant 1R01MH129833 (Hardan & Uljarevic) by the National Institute of Mental Health. Dr. Hardan has received grant or research support from the National Institutes of Health, Autism Speaks, and the Simons Foundation Autism Research Initiative. He has served on the advisory board/Data and Safety Monitoring Board of Roche. He has co-authored the Stanford Social Dimensions Scale (SSDS). He has served as a consultant to BioBridge, Roche, Finch Therapeutics, and the PTEN Research Foundation and has equity options in iSCAN-R and AI-Measures. He has served on the editorial boards of the Journal of Autism and Developmental Disorders and Child Psychiatry and Human Development. He has held patents (in preparation, filed, or granted) on N-acetyl cysteine, pregnenolone, and arginine vasopressin. Dr. Frazier has received funding or research support from, acted as a consultant to, received travel support from, and/or received a speaker’s honorarium from the PTEN Research Foundation, SYNGAP Research Fund, Malan Syndrome Foundation, ADNP Kids Research Foundation, Quadrant Biosciences, Autism Speaks, Impel NeuroPharma, F. Hoffmann-La Roche AG Pharmaceuticals, the Cole Family Research Fund, Simons Foundation, Ingalls Foundation, Forest Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol-Myers Squibb, Roche Pharma, MaraBio, Scioto Biosciences, National Institutes of Health, and the Brain and Behavior Research Foundation, has equity options in Quadrant Biosciences/Autism Analytica, MaraBio, and Springtide, and has an investor stake in Autism EYES LLC. Dr. McPartland consults with Customer Value Partners, Bridgebio, Determined Health, Apple, Neumarker, and BlackThorn Therapeutics, has received research funding from Janssen Research and Development, serves on the Scientific Advisory Boards of Pastorus and Modern Clinics, and receives royalties from Guilford Press, Lambert, Oxford, and Springer. His effort was supported by NIMH U19 MH108206. Dr. Youngstrom is the co-founder and Executive Director of Helping Give Away Psychological Science, a 501c3; he has consulted about psychological assessment with Signant Health and received royalties from the American Psychological Association and Guilford Press, and he holds equity in Joe Startup Technologies. Dr. Uljarević has received grant or research support from the National Institute of Mental Health, Simons Foundation, Autism Speaks and PTEN Research. He serves on the editorial boards of the Journal of Autism and Developmental Disorders, PLOS One, Frontiers in Psychiatry, and Frontiers in Neuroscience, and has co-authored the Stanford Social Dimensions Scale (SSDS). Drs. Chetcuti and Loth have no financial interests or potential conflicts of interests to declare.
References
-
- Stallworthy IC, Berry D, Davis S, Wolff JJ, Burrows CA, Swanson MR, et al. Quantifying latent social motivation and its associations with joint attention and language in infants at high and low likelihood for autism spectrum disorder. Dev Sci. 2023;26:e13336. - PubMed
-
- Su PL, Rogers SJ, Estes A, Yoder P. The role of early social motivation in explaining variability in functional language in toddlers with autism spectrum disorder. Autism. 2021;25:244–57. - PubMed
-
- Ritsner MS, Ratner Y, Mendyk N, Gooding DC. The characterization of social anhedonia and its correlates in schizophrenia and schizoaffective patients. Psychiatry Res. 2018;270:922–8. - PubMed
-
- Neuhaus E, Bernier RA, Webb SJ. Social motivation across multiple measures: caregiver-report of children with ASD. Autism Res. 2021;14:369–79. - PubMed
Publication types
Grants and funding
- 1R01MH129833/U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
- 1R01MH129833/U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
- 1R01MH129833/U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
- 1R01MH129833/U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
LinkOut - more resources
Full Text Sources